1.	Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SDX-105-03, NCT00139841
2.	FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000616169, GCLLSG-CLL10, 2007-007587-21, CLL10, EUDRACT-2007-007587-21, EU-20883, ROCHE-GCLLSG-CLL10, NCT00769522
3.	Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C18083/3064/NL/MN, NCT00877006
4.	Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C18083/3070, NCT01073163
5.	Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14293A, NCT01500083
6.	Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: ZOHT-01/07, 26866138LYM1003, NCT00426855
7.	Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000633771, OSU-08164, 2008C0131, NCCN-C03, NCT00834678
8.	Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C18083/1063/MM/US, NCT00920855
9.	Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: AGMT CLL-6 BendAlem, NCT00951457
10.	Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 1 to 20 Sponsor: Pharmaceutical / Industry Protocol IDs: C18083/2046, 2010-020768-40, NCT01088984
11.	Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 60 and over Sponsor: NCI, Other Protocol IDs: 2413.00, NCI-2010-01253, K12CA076930, NCT01141725
12.	Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 16201, NCT01188681
13.	Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02536, OSU-10040, U01CA076576, CDR0000687197, 8600, NCT01238146
14.	Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1108-CA, PCI-32765, NCT01292135
15.	SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SDX-105-02, NCT00076349
16.	Phase II Study of Bendamustine in Patients With Rituximab-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0311059-01, SALMEDIX-SDX-105-01, NCT00085033
17.	Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: jth_002, NCT00204620
18.	Phase II Study of Bendamustine and Mitoxantrone Hydrochloride in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Closed Age: Not specified Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL2K, EU-20551, RIBOSEPHARM-GCLLSK-CLL2K, NCT00274963
19.	Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: 2007002, NCT00612183
20.	A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C05011, NCT00636792
21.	Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 08-041, NCT00705250
22.	Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 6803, NCI-2010-00714, UWCC-6803, FHCRC-6803, IR-6803, NCCN-C01, NCT00823797
23.	Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: PI-08904, IND Exemption Number 103985, NCT00831597
24.	Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: ULYM07054, NCT00547534
25.	Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 08-1137-04, NCT00867503